Status:
COMPLETED
RECOVER:Comparison of Renal Toxicity Between Visipaque(Iodixanol)and Hexabrix(Ioxaglate)in Renal Insufficiency Undergoing Coronary Angiography
Lead Sponsor:
Seoul National University Hospital
Conditions:
Kidney Failure
Eligibility:
All Genders
19+ years
Phase:
PHASE4
Brief Summary
In the treatment of coronary heart disease which is the major cause of heart attack, direct mechanical treatment with catheters such as the coronary angiography,coronary balloon intervention and stent...
Detailed Description
Iodixanol, a nonionic, dimeric, iso-osmolar contrast medium (IOCM), may be less nephrotoxic than nonionic, monomeric, low-osmolar contrast media (LOCMs) in high-risk patients. We compared the nephroto...
Eligibility Criteria
Inclusion
- creatinine clearance rates ≤60 mL/min using the Cockcroft-Gault formula
- Patients who undergo coronary catheterization
- Age of 19 or over 19.
Exclusion
- pregnancy
- lactation
- having received contrast media within 7 days of study entry
- emergent coronary angiography
- acute renal failure
- end-stage renal disease requiring dialysis
- history of hypersensitivity reaction to contrast media
- cardiogenic shock
- pulmonary edema
- multiple myeloma
- mechanical ventilation
- parenteral use of diuretics
- use of N-acetylcysteine
- use of metformin or nonsteroidal anti-inflammatory drugs within 48 hours of the procedure.
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2004
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00247325
Start Date
January 1 2004
End Date
December 1 2004
Last Update
November 30 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital , Cardiovascular Center
Seoul, South Korea